# US 2021/0263046 A1 · Antibodies and Immunoassays for Detection of BMP-15 and GDF-9 Isoforms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0263046 A1
- Document ID: US20210263046A1
- Status: Published application
- Kind: A1
- Application number: 16/497,046
- Filed: 2018-03-26
- Published: 2021-08-26
- Earliest claimed: 2017-03-24
- Assignees: Ansh Labs, LLC
- Applicants: Ansh Labs LLC
- Inventors: Gopal V. SAVJANI; Ajay KUMAR; Bhanu KALRA
- Web page: https://patentgrep.com/patent/US20210263046A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2333/495: Transforming growth factor [TGF]
- G01N 2333/51: Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- G01N 2800/367: Infertility, e.g. sperm disorder, ovulatory dysfunction
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods for quantifying GDF-9-BMP-15 heterodimers and GDF-9 and BMP-15 homodimers using antibodies directed to epitopes in GDF-9 and BMP-15 in a sandwich ELISA are provided. Also provided are kits for quantifying the heterodimers.

## Claims

### Claim 1

A method of quantifying GDF-9-BMP-15 heterodimers in a sample, the method comprising:
performing an immunoassay on the sample using a first antibody that specifically binds to an epitope of GDF-9 and a second antibody that specifically binds to an epitope of BMP-15, wherein one of said first and second antibodies is used for capture and the other is used for detection step of the immunoassay;
measuring a detection signal generated by an agent conjugated to the detection antibody; and
quantifying the amount of GDF-9-BMP-15 heterodimers in the sample by comparing the detection signal to a calibration curve correlating an amount of GDF-9-BMP-15 heterodimer to the detection signal.

### Claim 2 (depends on 1)

The method of claim 1, wherein the immunoassay is a sandwich ELISA.

### Claim 3 (depends on 1)

The method of claim 1, wherein the step of measuring a detection signal comprises measuring a fluorescence signal or a chemiluminiscence signal.

### Claim at position 4

-6. (canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the sample is follicular fluid.

### Claim 8 (depends on 1)

The method of claim 1, wherein the immunoassay is performed in the presence of one or more protein dissociating agents.

### Claim 9 (depends on 8)

The method of claim 8, wherein the one or more protein dissociating agents are selected from the group consisting of Triton-X 100, guanidinium chloride, sodium dodecyl sulfate (SDS), urea, thiourea, lithium perchlorate, lithium acetate, and magnesium chloride.

### Claim at position 8

-12. (canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein the first antibody specifically binds to an epitope of GDF-9 contained in an amino acid sequence selected from SEQ ID NOS: 111, 119, 120, 123-125, 128-136, and 144-146; and wherein the second antibody binds to an epitope of BMP-15 contained in an amino acid sequence selected from SEQ ID NOS: 8-12, 28, 30, 32-34, 40, 41, 45, 46, 48-51, 55, 61, and 68.

### Claim 14 (depends on 13)

The method of claim 13, wherein the first antibody specifically binds to an epitope of GDF-9 contained in an amino acid sequence selected from SEQ ID NOS: 111, 119, 120, 123-125, 128-136, and 144-146; and the second antibody binds to an epitope of BMP-15 contained in an amino acid sequence selected from SEQ ID NOS: 8, 9, 12, 32, and 33.

### Claim 15

A method of quantifying BMP-15 homodimer in a sample, the method comprising performing an immunoassay on the sample using the same anti-BMP-15 antibody for both capture and detection steps of the immunoassay, wherein the antibody specifically binds an epitope contained in an amino acid sequence selected from SEQ ID NOS: 8-12, 28, 30, 32-34, 40, 41, 45, 46, 48-51, 55, 61, and 68;
measuring a detection signal generated by an agent conjugated to the anti-BMP-15 antibody used for detection step; and
quantifying the amount of BMP-15 homodimer in the sample by comparing the detection signal to a calibration curve correlating an amount of BMP-15 homodimer to the detection signal.

### Claim 16 (depends on 15)

The method of claim 15, wherein the immunoassay is a sandwich ELISA.

### Claim 17 (depends on 15)

The method of claim 15, wherein the measuring a detection signal comprises measuring a fluorescence signal or a chemiluminiscence signal.

### Claim 18

(canceled)

### Claim 19 (depends on 15)

The method of claim 15, wherein the antibody specifically binds an epitope contained in an amino acid sequence selected from SEQ ID NOS: 8 and 9.

### Claim 20 (depends on 15)

The method of claim 15, wherein the antibody specifically binds an epitope contained in an amino acid sequence selected from SEQ ID NOS: 32 and 33.

### Claim 21

A method of quantifying GDF-9 homodimer in a sample, the method comprising:
performing an immunoassay on the sample using the same anti-GDF-9 antibody for both capture and detection steps of the immunoassay, wherein the antibody specifically binds an epitope contained in an amino acid sequence selected from SEQ ID NOS: 111, 119, 120, 123-125, 128-136, and 144-146;
measuring a detection signal generated by an agent conjugated to the anti-GDF-9 antibody used for detection step; and
quantifying the amount of GDF-9 homodimer in the sample by comparing the detection signal to a calibration curve correlating an amount of GDF-9 homodimer to the detection signal.

### Claim 22 (depends on 21)

The method of claim 21, wherein the immunoassay is a sandwich ELISA.

### Claim 23 (depends on 21)

The method of claim 21, wherein the measuring a detection signal comprises measuring a fluorescence signal or a chemiluminiscence signal.

### Claim 24

(canceled)

### Claim 25 (depends on 21)

The method of claim 21, wherein the immunoassay is performed in the presence of one or more protein dissociating agents.

### Claim at position 22

-29. (canceled)

### Claim 30

A kit for quantifying GDF-9-BMP-15 heterodimers, the kit comprising an anti-GDF-9 antibody, an anti BMP-15 antibody, wherein the anti-GDF-9 antibody specifically binds an epitope contained in an amino acid sequence selected from SEQ ID NOS: 111, 119, 120, 123-125, 128-136, and 144-146, and wherein the anti-BMP-15 antibody specifically binds to an epitope contained in an amino acid sequence selected from SEQ ID NOS: 8-12, 28, 30, 32-34, 40, 41, 45, 46, 48-51, 55, 61, and 68.

### Claim at position 24

-52. (canceled)

### Claim 53 (depends on 15)

The method of claim 15, wherein the immunoassay is performed in the presence of one or more protein dissociating agents.
